Ozanimod, an Oral S1P Receptor Modulator, Is Effective and Well-Tolerated in the Long-Term Treatment of Moderate to Severe Ulcerative Colitis

Feagan, B G; William, Sandborn; Geert, DʼHaens; Hanauer, Stephen B.; Douglas, W; Vermeire, Séverine; David, Paul; Petersen, AnnKatrin; Liu, Jerry; Aranda, Richard; Allan, Olson

doi:10.14309/00000434-201802001-00012

Cited by 1 publication

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ozanimod caused marked decreases in cells expressing C-C motif chemokine receptor 7 and variable decreases in subsets lacking C-C motif chemokine receptor 7. After the promising results from a randomised, placebo-controlled, phase II trial of ozanimod in relapsing multiple sclerosis (RADIANCE) were released, 69,70 the efficacy and safety of ozanimod for adults with relapsing multiple sclerosis was further evaluated in the randomised, doubleblind, double-dummy, and multinational phase III SUNBEAM and RADIANCE. 71,72 SUNBEAM was a minimum 12-month phase III trial done at 1346 participants who were randomly assigned to ozanimod 1.0 mg (n = 447), ozanimod 0.5 mg (n = 451), or IFNβ-1a (n = 448).…”

Section: Are Observed In a T-cell Adoptive Transfer Colitis Model Indicatingmentioning

confidence: 99%

Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis ‐ a unique therapeutic target in inflammatory bowel disease

Wang

Goren

Yang

et al. 2021

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Background: Ozanimod, a high selective sphingosine 1 phosphate (S1P) receptor (S1PR) 1/5 modulator was approved by the Food and Drug Administration for the treatment of adult patients with moderately to severely active ulcerative colitis.Additional S1PR modulators are being tested in clinical development programmes for both ulcerative colitis and Crohn's disease. Aim:To provide an overview of advances in understanding S1PRs biology and summarise preclinical and clinical investigations of S1P receptor modulators in chronic inflammatory disease with special emphasis on inflammatory bowel diseases (IBD). Methods:We performed a narrative review using PubMed and Clini calTr ials.gov.Results: Through S1PRs, S1P regulates multiple cellular processes, including proliferation, migration, survival, and vascular barrier integrity. The S1PRs function of regulating lymphocyte trafficking is well known, but new functions of S1PRs expand our knowledge of S1PRs biology. Several S1PR modulators are in clinical development for both ulcerative colitis and Crohn's disease and have shown promise in phase II and III studies with ozanimod now being approved for ulcerative colitis.

show abstract

Section: Are Observed In a T-cell Adoptive Transfer Colitis Model Indicatingmentioning

confidence: 99%

Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis ‐ a unique therapeutic target in inflammatory bowel disease

Wang

Goren

Yang

et al. 2021

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Ozanimod, an Oral S1P Receptor Modulator, Is Effective and Well-Tolerated in the Long-Term Treatment of Moderate to Severe Ulcerative Colitis

Cited by 1 publication

References 1 publication

Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis ‐ a unique therapeutic target in inflammatory bowel disease

Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis ‐ a unique therapeutic target in inflammatory bowel disease

Contact Info

Product

Resources

About